Searched for: person:yazicy01
in-biosketch:true
Are Disease Classification Criteria for Diagnosis or for Research? In Fact, for Neither [Editorial]
Yazici, Hasan; Yazici, Yusuf
PMID: 37914213
ISSN: 1499-2752
CID: 5633042
Introduction, Vasculitis 2023
Yazici, Hasan; Yazici, Yusuf
PMID: 38015004
ISSN: 1531-6963
CID: 5617362
Current treatment approach to ANCA-associated vasculitis
Yazici, Yusuf
PURPOSE OF REVIEW/OBJECTIVE:This review will attempt to summarize the most potentially impactful new data on the way ANCA-associated vasculitis (AAV) is diagnosed, treated, and monitored. RECENT FINDINGS/RESULTS:The newly developed classification criteria for AAV have serious methodological issues that need to be addressed before they are widely adopted. The newly approved drugs and studies into both achieving remission and maintaining it have added to our overall knowledge of managing AAV and should hopefully contribute to improving outcomes in AAV. SUMMARY/CONCLUSIONS:The diagnosis, treatment and monitoring of AAV have seen major improvements in the last two years. The remaining issues outlined in this review still need to be addressed to best serve AAV patients.
PMID: 37755381
ISSN: 1531-6963
CID: 5611532
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study
Fineman, Mark S; McAlindon, Timothy E; Lattermann, Christian; Swearingen, Christopher J; Kennedy, Sarah; Lopez, Victor A; Simsek, Ismail; Tambiah, Jeyanesh R S; Yazici, Yusuf
INTRODUCTION/BACKGROUND:Knee osteoarthritis (OA) is a common painful disorder. Intra-articular (IA) corticosteroid injections are frequently prescribed to treat knee pain. Lorecivivint (LOR), a novel IA cdc2-Like Kinase (CLK)/Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase (DYRK) inhibitor thought to modulate Wnt and inflammatory pathways, has appeared safe and demonstrated improved patient-reported outcomes compared with placebo. While LOR is proposed for stand-alone use, in clinical practice, providers might administer LOR in close time proximity to IA corticosteroid. This open-label, parallel-arm, healthy volunteer study assessed potential short-term safety, tolerability and pharmacokinetic (PK) interactions between IA LOR and triamcinolone acetonide (TCA) administered 7 days apart. METHODS:Healthy volunteers were randomized to Treatment Sequence 1 (IA 40 mg TCA followed by IA 0.07 mg LOR) or Treatment Sequence 2 (IA 0.07 mg LOR followed by IA 40 mg TCA). Treatment-emergent adverse events (TEAEs) were categorized by "epoch", with epoch 1 spanning from first until second injection, and epoch 2 spanning from second injection until end of study. Plasma PK was assessed pre injection and out to 22 days after to assess PK treatment interaction. RESULTS:A total of 18 TEAEs were reported by 11 (27.5%) of 40 enrolled participants, and there were no serious adverse events. Thirteen TEAEs were reported in Treatment Sequence 1 and five in Treatment Sequence 2, similarly distributed between epochs 1 and 2. In all participants and at all time points, plasma LOR concentrations were below the limit of quantification (0.100 ng/mL). Geometric mean concentrations and PK parameters for TCA were similar between treatment sequences. CONCLUSION/CONCLUSIONS:No safety signals were observed. There were no quantifiable plasma concentrations of LOR in either Treatment Sequence. The PK of TCA was unaffected by previous LOR injection. These results suggest that IA administration of LOR and TCA in close time proximity is unlikely to pose a safety concern. TRIAL REGISTRATION/BACKGROUND:ClinicalTrials.gov identifier, NCT04598542.
PMCID:10654271
PMID: 37902943
ISSN: 2198-6576
CID: 5736452
A probable ecologic bias in the article on the progression of knee osteoarthritis: comment on the article by Lo et al [Comment]
Yazici, Hasan; Ogun, Hande; Yazici, Yusuf
PMID: 36940246
ISSN: 2326-5205
CID: 5606692
Behçet Syndrome
Hatemi, Gülen; Uçar, Didar; Uygunoğlu, Uğur; Yazici, Hasan; Yazici, Yusuf
Behçet's syndrome is a systemic vasculitis affecting arteries and veins of all sizes as well as recurrent oral, genital, and intestinal ulcers, skin lesions, predominantly posterior uveitis, and parenchymal brain lesions. These can be present in various combinations and sequences over time and diagnosis is made by recognizing the manifestations, as there are no diagnostic biomarkers or genetic tests. Treatment modalities include immunomodulatory agents, immunosuppressives and biologics, tailored according to prognostic factors, disease activity, severity, and patients' preferences.
PMID: 37331734
ISSN: 1558-3163
CID: 5533692
Correspondence on 'classification criteria: time for a rethink 'by D Porter et al' [Letter]
Yazici, Hasan; Yazici, Yusuf
PMID: 32938636
ISSN: 1468-2060
CID: 4593182
Outcome measures in Behçet syndrome
Hatemi, Gülen; Yazici, Yusuf
Disease assessment has been challenging in Behçet syndrome due to the heterogeneous disease course and multiorgan involvement with variable treatment response. There have been several recent improvements regarding outcome measures including development of a Core Set of Domains for Behçet syndrome and novel instruments for assessing specific organs and overall damage. This review focuses on the current state of outcome measures in Behçet syndrome, unmet needs, and a research agenda towards the development of standardized and validated outcome measure instruments.
PMID: 37100337
ISSN: 1521-7035
CID: 5465182
Difficult-to-treat Behçet syndrome: A therapeutic approach
Yazici, Yusuf; Hatemi, Gulen
Behcet syndrome is a systemic vasculitis which can involve many different organ systems. As such, treatment decisions need to be based on organ system involved. In addition, specific patient characteristics potentially predict milder or more severe course, and all these factors need to be taken into consideration when making treatment decisions. In this paper, we review the current approaches to treating Behcet syndrome patients.
PMID: 36822253
ISSN: 1521-7035
CID: 5462272
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis
Yazici, Hasan; Tascilar, Koray; Yazici, Yusuf
PURPOSE OF REVIEW/OBJECTIVE:A critique of the recently published classification criteria for three main types of antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. RECENT FINDINGS/RESULTS:An ACR and EULAR joint task force recently published classification criteria for three main types of ANCA-associated vasculitis. The criteria were based on patient histories and findings in nearly 7000 patients from 136 sites in 32 countries. As such the study represented hitherto the most intensive attempt to prepare classification criteria vasculitis. We propose, this truly intensive effort was, unfortunately, unsuccessful. There were two main mishaps. The first one was that the proposed criteria were not validated in an independent cohort. This is curious in that the sponsors, ACR and EULAR, require such independent cohorts for validation. The second mishap is that the concept that disease classification criteria need to be 100% sensitive and specific for a diagnosis is unrealistic. Moreover, all-purpose disease classification criteria are not respectful to scientific research and to the probabilistic nature of the art and the science of medicine. SUMMARY/CONCLUSIONS:The new ACR/EULAR ANCA-associated vasculitis guidelines have not been validated in independent cohorts. We propose replacing the term disease criteria with disease guidelines.
PMID: 36382396
ISSN: 1531-6963
CID: 5381632